Fig. 2From: The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational studyAÂ PFS in patients with EGFR-mutant NSCLC treated with dacomitinib and afatinib; BÂ TTF in patients with EGFR-mutant NSCLC treated with dacomitinib and afatinib. EGFR, epidermal growth factor receptor; PFS, progression-free survival; TTF, time to treatment failureBack to article page